Omeros (OMER) Other Operating Expenses (2012 - 2026)
Omeros (OMER) posted Other Operating Expenses of $587000.0 for Q1 2026, down 97.8% sequentially from $26.7 million in Q4 2020.
Omeros (OMER) Other Operating Expenses (2012 - 2026) Analysis & Trends
Omeros has reported Other Operating Expenses for 9 years, with the latest figure at $587000.0 in Q1 2026.
- Quarterly Other Operating Expenses changed N/A year-over-year to $587000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $587000.0 (changed N/A YoY) and the FY2025 annual result came in at $237.6 million, changed N/A from the prior year.
- Other Operating Expenses retreated to $587000.0 in Q1 2026 per OMER's latest filing, from $26.7 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $587000.0 in Q1 2026 and troughed at $587000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 798,000.00 |
| Mar 31, 2026 | 587,000.00 |
| Dec 31, 2020 | 26.68 Mn |
| Sep 30, 2020 | 401,000.00 |
| Jun 30, 2020 | 147,000.00 |
| Mar 31, 2020 | 267,000.00 |
| Dec 31, 2019 | 28.68 Mn |
| Sep 30, 2019 | 278,000.00 |
| Jun 30, 2019 | 55,000.00 |
| Mar 31, 2019 | 131,000.00 |
| Dec 31, 2018 | 157,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 116,000.00 |
| Mar 31, 2018 | 203,000.00 |
| Dec 31, 2017 | 466,000.00 |
| Sep 30, 2017 | 184,000.00 |
| Jun 30, 2017 | 157,000.00 |
| Mar 31, 2017 | 271,000.00 |
| Dec 31, 2016 | 380,000.00 |
| Sep 30, 2016 | 378,000.00 |